# Aflibercept Time-Based T&T Protocol (Fixed q8w)
# Time-based disease progression with visit-based measurements

# Metadata
name: "Aflibercept Time-Based T&T (Fixed q8w)"
version: "1.0"
created_date: "2025-06-21"
author: "Calibration Team"
description: "Time-based fixed dosing protocol: VIEW 2q8 extended indefinitely with minimal monitoring"

# Model type indicator - TIME-BASED
model_type: "time_based"
transition_model: "fortnightly"
update_interval_days: 14  # Disease state updates every 2 weeks

# Protocol parameters - FIXED dosing (not treat-and-extend)
protocol_type: "fixed"

# Loading dose phase
loading_dose_injections: 3  # Number of initial monthly injections
loading_dose_interval_days: 28  # Monthly (4 weeks) during loading

# Fixed dosing phase (after loading) - bimonthly
min_interval_days: 56  # 8 weeks always
max_interval_days: 56  # 8 weeks - no extension
extension_days: 0      # No extension - fixed schedule
shortening_days: 0     # No shortening - fixed schedule

# Reference to parameter files (relative to this file)
disease_transitions_file: "parameters/disease_transitions.yaml"
treatment_effect_file: "parameters/treatment_effect.yaml"
vision_parameters_file: "parameters/vision.yaml"
discontinuation_parameters_file: "parameters/discontinuation.yaml"
demographics_parameters_file: "parameters/demographics.yaml"

# Baseline vision distribution - UK real-world (identical to T&E)
baseline_vision_distribution:
  type: beta_with_threshold
  alpha: 3.5
  beta: 2.0
  min: 5
  max: 98
  threshold: 70
  threshold_reduction: 0.6

# Clinical improvements - standard response distribution
clinical_improvements:
  enabled: true
  use_loading_phase: true
  use_time_based_discontinuation: true
  use_response_based_vision: true
  use_baseline_distribution: false  # Use protocol's beta distribution
  use_response_heterogeneity: true
  
  # Standard response distribution (VIEW-like)
  # Response type doesn't affect intervals in fixed protocol
  response_types:
    good:
      probability: 0.30    # 30% good responders
      multiplier: 1.8      # Better vision gains
    average:
      probability: 0.50    # 50% average responders
      multiplier: 1.0      # Normal vision gains
    poor:
      probability: 0.20    # 20% poor responders
      multiplier: 0.5      # Reduced vision gains
  
  # Discontinuation probabilities - identical to T&E
  discontinuation_probabilities:
    1: 0.10   # 10% Year 1
    2: 0.15   # 15% Year 2 
    3: 0.12   # 12% Year 3
    4: 0.08   # 8% Year 4
    5: 0.075  # 7.5% Year 5+
  
  # Vision response parameters - identical to T&E
  vision_response_params:
    loading:
      mean: 4.0
      std: 1.5
    year1:
      mean: 1.0
      std: 1.0
    year2:
      mean: 0.0
      std: 1.0
    year3plus:
      mean: -0.3
      std: 1.0

# Minimal monitoring assumption for T&T
monitoring:
  oct_frequency: "quarterly"  # vs monthly for T&E
  safety_visits_only: false   # Still full visits but less imaging

# Target outcomes for validation
target_outcomes:
  year1:
    mean_bcva_change: 7.5    # 7-8 letters expected (better than T&E)
    mean_injections: 7.5     # Fixed 7.5 injections
  year2:
    mean_bcva_change: 7.0    # Maintained efficacy
    cumulative_injections: 13.5  # 6 more in year 2